Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Phase III VERONA study of venetoclax with azacitidine in treatment-naïve higher-risk MDS

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the randomized, double-blind Phase III VERONA study (NCT04401748), a trial-in-progress evaluating venetoclax with azacitidine to assess the change in complate remission and overall survival in treatment-naive higher risk myelodsyplastic syndromes (MDS). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.